Intuitive Surgical (NasdaqGS:ISRG) received U.S. FDA clearance for its da Vinci 5 system for specific minimally invasive ...

Intuitive Surgical is the worldwide leader in robotic surgery, and this has helped the company build a long track record of ...

Intuitive Surgical's stock is prone to drawdowns, and January could be an opening for long-term growth investors.

Intuitive Surgical, Inc. (ISRG) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea ...

With nine new procedures cleared for the da Vinci 5 robot, Intuitive’s strategy includes working with a limited number of U.S ...

Intuitive Surgical ISRG delivered robust 2025 results, beating estimates on both counts. Total revenues rose 20.5% year over ...

The FDA 510(k) clearances for cardiac procedures cover Intuitive's latest-generation da Vinci 5 (DV5) using non-Force Feedback instruments.

Detailed price information for Intuitive Surg Inc (ISRG-Q) from The Globe and Mail including charting and trades.

Intuitive Surgical has received FDA clearance for cardiac procedures using the da Vinci 5 surgical robot, according to a Jan. 26 report from Mass Device. The new cardiac clearances cover mitral valve ...

Intuitive Surgical looks like a long-term buy: strong Da Vinci 5 adoption, expanding FDA use cases, and multiyear-low valuation. Click here to read more.

Intuitive Surgical's newest model of its flagship device should make progress through 2031. The company will face a more competitive market moving forward. Intuitive Surgical's prospects still look ...

Intuitive Surgical (NASDAQ: ISRG) reports in-line Q4 results, sets measured guidance for 2026, with an 18% revenue growth and $2.53 EPS.